巴瑞替尼快速改善特应性皮炎四项EASI临床体征
本文为三项III期双盲16周试验的事后分析,评估巴瑞替尼单药(BREEZE-AD1/AD2)及联合外用糖皮质激素(BREEZE-AD7)对EASI各临床子评分的影响。结果显示巴瑞替尼4 mg在两项队列中均快速且持续改善四项体征,瘙痒相关抓痕改善最显著。
要点
- 巴瑞替尼4 mg在第1周即改善抓痕、水肿/丘疹和红斑,并维持至第16周。
- 苔藓化改善出现较早,单药第1周、联合治疗第2周,且持续改善无平台期。
- 抓痕子评分改善幅度最大,提示瘙痒-搔抓循环被早期打断。
核心结论
- 巴瑞替尼治疗可快速且持续改善特应性皮炎炎症相关临床体征,对抓痕的改善尤为突出。
- 选择性抑制JAK1/JAK2可能快速控制皮肤炎症,瘙痒快速减轻有助于早期打断瘙痒-搔抓循环。
研究设计与样本
- 三项III期双盲16周试验的事后分析,采用混合模型重复测量(MMRM)分析EASI各子评分较基线的百分比变化。
- 单药治疗队列为BREEZE-AD1/BREEZE-AD2,联合外用糖皮质激素队列为BREEZE-AD7。
主要发现
- 巴瑞替尼4 mg在两队列中均快速且持续改善抓痕、水肿/丘疹、红斑和苔藓化四项体征。
- 单药及联合治疗中,抓痕、水肿/丘疹和红斑评分第1周即出现显著改善(单药p<0.001;联合治疗p<0.001、p<0.01、p<0.001),第4周达平台,至第16周仍显著优于安慰剂。
- 苔藓化评分单药第1周(p<0.05)、联合治疗第2周(p<0.001)即出现改善,持续改善无明确平台。
- 抓痕评分改善幅度最大,单药第1周接近最大降幅,联合治疗各时间点均保持最高。
关键数值与推荐
- 巴瑞替尼4 mg单药第1周抓痕、水肿/丘疹、红斑评分较基线显著改善(p<0.001)。
- 巴瑞替尼4 mg联合TCS第1周抓痕、水肿/丘疹、红斑评分显著改善(分别为p<0.001、p<0.01、p<0.001)。
- 苔藓化评分单药第1周(p<0.05)、联合治疗第2周(p<0.001)出现改善。
临床怎么用
- 临床可预期巴瑞替尼4 mg在治疗早期(第1周)即改善抓痕、水肿/丘疹和红斑,苔藓化改善稍晚但持续。
- 对瘙痒-搔抓循环突出的AD患者,早期抓痕改善可作为疗效观察指标之一。
局限性
- 本文为事后分析,原文摘要未报告样本量、置信区间及全部安全性数据。
- 仅分析EASI临床子评分,未涉及其他终点或长期数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Baricitinib treatment in adults with moderate-to-severe atopic dermatitis (AD) has demonstrated rapid improvements in itch as well as AD sign severity and affected body surface area as assessed by the Eczema Area and Severity Index (EASI) total score, whether administered as monotherapy or in combination with topical corticosteroids (TCS). As EASI clinical signs differ in time course and associated antecedents, the effects of baricitinib on each individual clinical sign are of interest. OBJECTIVES: In this post hoc analysis, we aimed to investigate the effects of baricitinib on individual EASI subscores, namely excoriation, oedema/papulation, erythema and lichenification, in both monotherapy and TCS combination therapy trials. METHODS: We analysed the percent change from baseline in individual EASI subscores from three phase-III, double-blind, 16-week trials of baricitinib in monotherapy (BREEZE-AD1/BREEZE-AD2) and TCS combination therapy (BREEZE-AD7) cohorts via mixed model repeated measures (MMRM). RESULTS: Baricitinib 4 mg showed rapid and sustained improvements in all four clinical signs in both cohorts. Significant effects emerged at week 1 for excoriation, oedema/papulation and erythema scores in monotherapy (p < 0.001) and TCS combination therapy (p < 0.001, p < 0.01, p < 0.001), plateaued at week 4, and remained significant versus placebo through week 16. The effect on lichenification scores also emerged early, at week 1 in monotherapy (p < 0.05) and week 2 in combination therapy (p < 0.001), with scores continuously improving without a clear plateau. Effect magnitude was highest in excoriation scores, exhibiting near-maximal reduction in week 1 of monotherapy and remaining highest across all timepoints in combination therapy. CONCLUSIONS: Rapid and sustained improvements were observed across clinical signs of inflammation and particularly on excoriation following baricitinib treatment. Our findings suggest that selective inhibition of janus kinases 1 and 2 leads to rapid and sustained control of skin inflammation, and that rapid reductions in itch translate into early disruption of the itch-scratch cycle.
引用
- Wollenberg A, Simon D, Kulthanan K, et al. Baricitinib treatment rapidly improves the four signs of atopic dermatitis assessed by Eczema Area and Severity Index (EASI) clinical subscores. J Eur Acad Dermatol Venereol. 2023. PMID: 38041556. doi:10.1111/jdv.19669
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。